PureTech Health plc (LON:PRTC)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 284.41M -6.2% |
| Revenue (ttm) | 4.80M -0.4% |
| Net Income | 1.59M -95.8% |
| EPS | 0.01 -96.1% |
| Shares Out | 245.18M |
| PE Ratio | 197.22 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 129,516 |
| Open | 116.20 |
| Previous Close | 116.00 |
| Day's Range | 114.80 - 117.00 |
| 52-Week Range | 107.40 - 143.60 |
| Beta | 0.78 |
| Analysts | Strong Buy |
| Price Target | 370.27 (+220.86%) |
| Earnings Date | Sep 22, 2026 |
About PureTech Health
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, a Phase 3-ready therapeutic candidate with the potential to establish a new standard of care (SOC) for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic lung diseases and LYT-200, a fully human IgG4 monoclonal antibody. The company also develops SPT-300, a Glyphed oral prodrug of allopregnanolone for the treatment of anxious depression; and delivers transformati... [Read more]
Analyst Summary
According to 4 analysts, the average rating for PRTC stock is "Strong Buy." The 12-month stock price target is 370p, which is an increase of 220.86% from the latest price.
News
PureTech Health H1 Earnings Call Highlights
PureTech Health NASDAQ: PRTC outlined progress across its portfolio in its 2026 half-year results call, highlighting external financings for Celea Therapeutics and Seaport Therapeutics, regulatory pro...
PureTech Health Earnings Call Transcript: H1 2026
H1 2026 saw major milestones: Seaport's $260M IPO, Celea's $180M financing and phase III start, and Gallop's Fast Track designation. Cash burn is set to drop sharply as late-stage costs shift to spun-out entities, with a strong runway through 2028 and a focus on capital returns to shareholders.
PureTech Health Quarterly report: H1 2026
PureTech Health has published its H1 2026 quarterly earnings report on September 22, 2026.
PureTech Announces Successful End-of-Phase 1 Meeting with U.S. Food and Drug Administration (FDA) and Receipt of Fast Track Designation for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS)
BOSTON--(BUSINESS WIRE)--PureTech Health plc (LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into val...
PureTech Health: Notice of Half-Yearly Results
BOSTON--(BUSINESS WIRE)--PureTech Health plc (LSE: PRTC) ("PureTech" or the "Company") plans to announce its half-yearly results for the six months ended 30 June 2026 on Tuesday 22 September 2026. A p...
PureTech Founded Entity Celea Therapeutics to Deliver Two Presentations at the Upcoming European Respiratory Society (ERS) Congress
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Celea Therapeutics to Deliver Two Presentations at the Upcoming European Respiratory Society (ERS) Congress.
PureTech Founded Entity Celea Therapeutics Doses First Patient in Global Phase 3 SURPASS-IPF Trial Evaluating Deupirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Celea Therapeutics Doses First Patient in Global Phase 3 SURPASS-IPF Trial Evaluating Deupirfenidone for the Treatment of IPF.
PureTech entity Celea raises $180 million to move lung disease drug into late stage trial
Celea Therapeutics, linked to PureTech Health , on Thursday completed a $180 million financing round for a late-stage trial of its lung disease drug, deupirfenidone, in patients with idiopathic pulm...
PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to IPF.
PureTech Health: Results of Annual General Meeting
BOSTON--(BUSINESS WIRE)--PureTech Health: Results of Annual General Meeting.
PureTech Health Earnings Call Transcript: H2 2025
Refined strategy emphasizes operational efficiency, early spin-outs, and disciplined capital allocation. Cash runway extends through 2028, with major progress in Celea and Gallop clinical programs and a focus on returning capital to shareholders after significant inflows.
PureTech Health Annual report: H2 2025
PureTech Health has published its H2 2025 annual report on April 29, 2026.
PureTech Health Annual report: H2 2025
PureTech Health has published its H2 2025 annual report on April 29, 2026.
PureTech Health Annual report: H2 2025
PureTech Health has published its H2 2025 annual report on April 29, 2026.
PureTech Health to delist American depositary shares from Nasdaq
PureTech Health (PRTC) announced that it has notified Nasdaq of its intention to voluntarily delist its American depositary shares, each representing the right to receive 10 ordinary shares of the…
PureTech Health announces data from Phase 1b trial of LYT-200
PureTech Health (PRTC) announced positive topline data from the completed Phase 1b clinical trial of LYT-200, a fully human anti-galectin-9 monoclonal antibody, in heavily pretreated patients with rel...
PureTech Health announces publication of Phase 2b ELEVATE IPF trial results
PureTech Health (PRTC) announced the publication of results from the Phase 2b ELEVATE IPF trial of deupirfenidone for the potential treatment of idiopathic pulmonary fibrosis in The American Journal o...
PureTech founded Seaport announces topline results from GlyphAgo trial
PureTech Health (PRTC) notes that its Founded Entity, Seaport Therapeutics, announced topline data from portions of its ongoing Phase 1 proof-of-concept clinical trial evaluating GlyphAgo. GlyphAgo is...
PureTech Health Transcript: Leerink Global Healthcare Conference 2026
The conference highlighted a robust hub-and-spoke model driving innovation and value through spin-outs, with strong clinical progress in IPF and oncology. Deupirfenidone is poised for a pivotal phase 3 trial, and the company remains self-funded with significant future milestones expected.
PureTech Health announces orphan drug designation for Deupirfenidone in IPF
PureTech Health (PRTC) announced that the U.S. Food and Drug Administration and European Commission have granted Orphan Drug Designation to deupirfenidone for the treatment of idiopathic pulmonary fib...
PureTech Health Transcript: 44th Annual J.P. Morgan Healthcare Conference
A diversified hub-and-spoke model drives innovation and financial returns by spinning out de-risked drug programs, with a strong track record of clinical and commercial success. Key assets Celea and Gallop are advancing to pivotal trials, while the company remains self-funded and focused on efficient capital allocation.
PureTech Health appoints Robert Lyne as CEO
PureTech Health (PRTC) announces that the board of directors has appointed Robert Lyne as CEO, and as a member of the board of directors, effective immediately. Lyne has served as…
PureTech Health completes LYT-100 End-of-Phase 2 meeting with FDA
PureTech Health (PRTC) announced the completion of the End-of-Phase 2 meeting with the FDA regarding the development of deupirfenidone, or LYT-100, for the treatment of idiopathic pulmonary fibrosis. ...
PureTech Health presents new analyses from ELEVATE IPF trial
PureTech Health (PRTC) announced the presentation of new analyses from the Phase 2b ELEVATE IPF trial of deupirfenidone for the treatment of idiopathic pulmonary fibrosis. The data show that the…
PureTech Health says Seaport Therapeutics doses first patient in GlyphAgo study
PureTech Health (PRTC) noted that its founded entity, Seaport Therapeutics, announced that the first participant has been dosed in the Phase 1 study of GlyphAgo.